

Please add the following new claim 20:

20. (New) A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that blocks the N-methyl-D-aspartate receptor or a major intracellular consequence of N-methyl-D-aspartate receptor activation, selected from pyrroloquinoline quinone and cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, the addictive substance being selected from the group consisting of alfentanil, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.

REMARKS

Claims 3 through 16 and 20 are now presented. New Claim 20 simply presents previous dependent claim 18 in independent form. The amendments to Claims 6-14 and 16 merely modify their dependency in view of the cancellation of Claim 1. It is believed this amendment places all claims in allowable form for grant in a reissue patent. Applicant respectfully requests that favorable action be taken at an early date.

Applicant stands ready to surrender the patent as soon as an Action is received indicating allowable claims. The undersigned invites the Examiner to telephone him if any issues arise which can be facilitated by a telephonic interview


Applicants attach hereto as pages A1 to A4, a reproduction of all of the claims now presented in accordance with 37 C.F.R. § 1.173(c).

The Commissioner is hereby authorized to charge any additional fees which may be required for the timely consideration of this amendment under 37 C.F.R. §§ 1.16 and 1.17, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3856-4006.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: March 17, 2005

By:



Arnold I. Rady
Registration No. 26,601

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101
Telephone 212-415-8552
Facsimile 212-415-8701